This short report describes the purpose, process and meetings of the Naloxone Reporting Short Life Working Group (SLWG). This report also describes the recommendations of the SLWG and outlines the next stage in this change process, where organisations will review these findings and respond to them.
A new report published by SDF shows the evaluation of the peer-to-peer naloxone programme within three pilot areas: one prison, one rural, one urban. The project aimed to establish, embed, and support high quality peer supply of naloxone as a core service across Scotland and ensure those involved in peer supply have an active voice in delivery of naloxone and other harm reduction interventions, including the sharing and promotion of good practice.
The Advisory Council of the Misuse of Drugs (ACMD) has reviewed the evidence on the provision and availability of naloxone in the UK, a medicine which can temporarily reverse the effects of opioids and is used as an emergency treatment for people who overdose on these drugs. The findings of this review, and recommendations to optimise the use of naloxone are presented in this report.
This report makes recommendations to the Mayor, Central Government and the Metropolitan Police Service (MPS) to help reduce the number of drug-related deaths across London and the UK.
Impacts of overdose: Evaluating the effects of grief and loss from overdose on people who inject drugs and developing an intervention to address them
Many people who inject drugs, and people who work in harm reduction services, are living with grief and loss stemming from the ongoing crisis of opioid-overdose related deaths. These experiences of loss can take a psychological toll, yet there are few bereavement services available for people with theses experiences.
The 2019 report from the European Monitoring Centre for Drugs and Drug Addiction has been released. This report presents a top-level overview of the drug phenomenon in Europe, covering drug supply, use and public health problems as well as drug policy and responses.